By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GATC Biotech subsidiary LifeCodexx said today that it has completed the recruitment of more than 500 blood samples for a clinical study of its non-invasive prenatal diagnostic test for trisomy 21.

The Konstanz, Germany-based company said that the prospective and blinded study will evaluate its sequencing-based PraenaTest against "conventional invasive methods."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.